AR029139A1 - Interleuquina 2 estabilizada - Google Patents

Interleuquina 2 estabilizada

Info

Publication number
AR029139A1
AR029139A1 ARP010102841A ARP010102841A AR029139A1 AR 029139 A1 AR029139 A1 AR 029139A1 AR P010102841 A ARP010102841 A AR P010102841A AR P010102841 A ARP010102841 A AR P010102841A AR 029139 A1 AR029139 A1 AR 029139A1
Authority
AR
Argentina
Prior art keywords
interleuquina
stabilized
variant
preferred formulation
reconstitution
Prior art date
Application number
ARP010102841A
Other languages
English (en)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24424265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR029139A1 publication Critical patent/AR029139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)

Abstract

Una preparacion farmacéutica estable que comprende interleuquina-2 Humana o una variante de la misma y una cantidad estabilizante de histidina. Una formulacion preferida incluye glicina y sacarosa y una variante de II-2 que tiene una mutacion simple, N88R. La formulacion preferida es una forma liofilizada, que con la reconstitucion con un diluyente acuoso, produce una solucion que tiene un pH que varía desde aproximadamente 5,0 a 6,5.
ARP010102841A 2000-06-28 2001-06-14 Interleuquina 2 estabilizada AR029139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/605,577 US6689353B1 (en) 2000-06-28 2000-06-28 Stabilized interleukin 2

Publications (1)

Publication Number Publication Date
AR029139A1 true AR029139A1 (es) 2003-06-04

Family

ID=24424265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102841A AR029139A1 (es) 2000-06-28 2001-06-14 Interleuquina 2 estabilizada

Country Status (24)

Country Link
US (1) US6689353B1 (es)
EP (1) EP1370280B1 (es)
JP (3) JP5522878B2 (es)
KR (1) KR100799402B1 (es)
CN (1) CN1523997B (es)
AR (1) AR029139A1 (es)
AU (1) AU2001273063A1 (es)
BR (1) BR0112101B1 (es)
CA (1) CA2413334C (es)
CO (1) CO5290308A1 (es)
CU (1) CU23536A3 (es)
DE (1) DE60142412D1 (es)
DO (1) DOP2001000197A (es)
EC (1) ECSP014106A (es)
ES (1) ES2344729T3 (es)
HN (1) HN2001000139A (es)
IL (2) IL153587A0 (es)
MX (1) MXPA03000046A (es)
MY (1) MY128629A (es)
PE (1) PE20020127A1 (es)
SV (1) SV2002000512A (es)
TW (1) TWI235063B (es)
UY (1) UY26805A1 (es)
WO (1) WO2002000243A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8531276B2 (en) * 2000-03-15 2013-09-10 Logitech Europe S.A. State-based remote control system
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003268664A1 (en) * 2002-09-26 2004-04-19 Shionogi And Co., Ltd. Stabilized protein compositions
EP3167961A1 (en) * 2004-04-08 2017-05-17 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
WO2006096497A2 (en) * 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2007106746A2 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2008260483A1 (en) * 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BR122013025625B1 (pt) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
US8519125B2 (en) * 2009-05-11 2013-08-27 Biomatrica, Inc. Compositions and methods for biological sample storage
SI2498801T1 (en) 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
ES2676373T3 (es) 2009-11-13 2018-07-19 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
JP5933544B2 (ja) 2010-07-26 2016-06-08 バイオマトリカ， インコーポレーテッド 外界温度で出荷および貯蔵中の血中ｄｎａ、ｒｎａおよびタンパク質ならびに他の生体試料を安定化させるための組成物
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
JP2014506116A (ja) 2010-11-12 2014-03-13 ウェルズ ファーゴ バンク ナショナル アソシエイション Ｉｌ−２部分とポリマーとのコンジュゲート
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
SG190418A1 (en) * 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
CN103063829B (zh) * 2012-12-21 2015-01-14 杭州茂天赛科技有限公司 一种冻存液
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
PL3180020T3 (pl) 2014-08-11 2019-06-28 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN113588501A (zh) 2015-12-08 2021-11-02 生物马特里卡公司 降低红细胞沉降速率
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
WO2019104092A1 (en) 2017-11-21 2019-05-31 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
IL308797A (en) 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. ANTI-MADCAM IMMUNE TOLERANCE
CR20220341A (es) 2019-12-17 2022-08-19 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
AU2021286177A1 (en) 2020-06-03 2022-12-01 Ascendis Pharma Oncology Division A/S IL-2 sequences and uses thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2023549191A (ja) * 2020-11-13 2023-11-22 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインターロイキン２の変異体又はその誘導体を含む医薬組成物及びその用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215631A (ja) * 1984-04-09 1985-10-29 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
JPH0229016A (ja) * 1989-06-09 1990-01-31 Alpine Electron Inc イコライザ装置
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU8985898A (en) * 1997-07-31 1999-02-22 Rhodia Chimie Cosmetic composition comprising a functionalised polyorganosiloxane
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
ECSP014106A (es) 2002-02-25
MXPA03000046A (es) 2003-06-19
PE20020127A1 (es) 2002-04-27
JP2015007114A (ja) 2015-01-15
JP2012211166A (ja) 2012-11-01
JP5989728B2 (ja) 2016-09-07
CU23536A3 (es) 2010-06-17
EP1370280B1 (en) 2010-06-16
EP1370280A2 (en) 2003-12-17
JP5522878B2 (ja) 2014-06-18
WO2002000243A2 (en) 2002-01-03
IL153587A (en) 2007-12-03
MY128629A (en) 2007-02-28
KR20030016312A (ko) 2003-02-26
JP2004532791A (ja) 2004-10-28
CA2413334A1 (en) 2002-01-03
UY26805A1 (es) 2002-01-31
CN1523997A (zh) 2004-08-25
HN2001000139A (es) 2003-12-11
KR100799402B1 (ko) 2008-01-30
CO5290308A1 (es) 2003-06-27
CA2413334C (en) 2011-03-08
WO2002000243A3 (en) 2003-10-02
CN1523997B (zh) 2010-09-01
ES2344729T3 (es) 2010-09-06
AU2001273063A1 (en) 2002-01-08
DE60142412D1 (de) 2010-07-29
BR0112101A (pt) 2004-07-06
DOP2001000197A (es) 2003-01-15
BR0112101B1 (pt) 2017-11-14
IL153587A0 (en) 2003-07-06
US6689353B1 (en) 2004-02-10
TWI235063B (en) 2005-07-01
SV2002000512A (es) 2002-07-03

Similar Documents

Publication Publication Date Title
AR029139A1 (es) Interleuquina 2 estabilizada
IT9019421A0 (it) Formulazioni acquose stabilizzate di piccoli peptidi.
MXPA05001841A (es) Formulacion de anticuerpos humanos para tratar trastornos asociados con tnfa.
CY1105465T1 (el) Μορφη δοσολογιας πepιλαμβανουσα υγρο σκευασμα
HRP20041152B1 (en) Pharmaceutical formulations
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
TR199901077A2 (en) �spen�iyari form�lasyonlar.
DE69522562D1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
TR200002812T2 (tr) Efervesan formülasyonları.
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
GT199900069A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
DE69723278D1 (de) Pharmazeutische ampulle
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
IS7097A (is) Lyfjablanda til að gefa fúlvestrant í vöðva
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
ES2038546B1 (es) Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
DE69602208D1 (de) Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
NO911988D0 (no) Stabiliserte vandige formuleringer av smaa peptider.
TH43906B (th) อินเทอร์ลูคิน 2 ที่ถูกทำให้เสถียรแล้ว

Legal Events

Date Code Title Description
FG Grant, registration